Distribution and Tissue Uptake of Poly(ethylene glycol) with Different Molecular Weights after Intravenous Administration to Mice

doi:10.1002/jps.2600830432

Journal of Pharmaceutical Sciences

Volume 83, Issue 4, April 1994, Pages 601-606

https://doi.org/10.1002/jps.2600830432 Get rights and content

Abstract

After intravenous (iv) injection of ¹²⁵I-labeled poly(ethylene glycol) (PEG) with different molecular weights to mice, the radioactivity of the organs was measured to pharmacokinetically analyze the body distribution of PEG according to a two-compartment model. High molecular weight PEGs were retained in the blood circulation for a longer period than low molecular weight PEGs. The terminal half-life of PEG in the circulation extended from 18 min to 1 day as the PEG molecular weight increased from 6000 to 190 000. PEG tended to accumulate in the tissues/organs such as muscle, skin, bone, and the liver to a higher extent than the other organs, irrespective of the molecular weight. The time dependence of tissue accumulation was based on the vascular permeability. The results of pharmacokinetic analysis suggested that small PEG tended to freely translocate from the circulation to extravascular tissues and to return to the blood circulation again by diffusion, whereas large PEG translocated more slowly to extravascular tissues. Urinary clearance decreased with increasing PEG molecular weight, similar to the tissue clearance, whereas liver clearance increased with the increasing PEG molecular weight, after passing a minimum around the molecular weight of 50 000. PEG uptake by Kupffer cells was enhanced as the molecular weight became > 50 000.

References and Notes (38)

Y. Ashihara et al.
Biochem. Biophys. Res. Commun.
(1978)
M. Leonard et al.
Biochem. Biophys. Acta.
(1984)
K. Ajisaka et al.
Biochem. Biophys. Res. Commun.
(1980)
J.S. Beckman et al.
J. Biol. Chem.
(1988)
F.M. Veronese et al.
J Controlled Release
(1989)
A. Abuchowski et al.
J Biol. Chem.
(1977)
K.V. Savoca et al.
Biochem. Biophys. Acta
(1979)
T. Sundqvist et al.
Computers Biomed. Res.
(1988)
J.M. Nigretto et al.
Biomaterials
(1989)
C.O. Beauchamp et al.
Anal. Biochem.
(1983)

D.L. Knook et al.

Exp. Cell Res.

(1976)

K.H. Nashat et al.

J. Hepatol.

(1985)

T. Yoshimoto et al.

Jpn. J. Cancer Res. (Gann).

(1986)

A. Bendich et al.

Clin. Exp. Immunol.

(1982)

M.S. Hershfield et al.

Engl. J. Med.

(1987)

N.V. Katre et al.

Proc. Natl. Acad. Sci. U.S.A.

(1987)

P.T. Pyatak et al.

Res. Commun. Chem. Pathol. Pharmacol.

(1980)

C.O. Beauchamp et al.

Anal. Biochem.

(1983)

F.M. Veronese et al.

J. Pharm. Pharmacol.

(1983)

Cited by (665)

Molecular Retention Limitations for Prevascularized Subcutaneous Sites for Islet Transplantation
2024, Biomacromolecules
Beta cell replacement therapies utilizing the subcutaneous space have inherent advantages to other sites: the potential for increased accessibility, noninvasive monitoring, and graft extraction. Site prevascularization has been developed to enhance islet survivability in the subcutaneous zone while minimizing potential foreign body immune responses. Molecular communication between the host and prevascularized implant site remains ill-defined. Poly(ethylene oxide)s (PEOs) of various hydrated radii (i.e., ∼11–62 Å) were injected into prevascularized subcutaneous sites in C57BL/6 mice, and the clearance and organ biodistribution were characterized. Prevascularization formed a barrier that confined the molecules compared with the unmodified site. Molecular clearance from the prevascularized site was inversely proportional to the molecular weight. The upper limit in molecular size for entering the vasculature to be cleared was determined to be 35 kDa MW PEO. These findings provide insight into the impact of vascularization on molecular retention at the injection site and the effect of molecular size on the mobility of hydrophilic molecules from the prevascularized site to the host. This information is necessary for optimizing the transplantation site for increasing the beta cell graft survival.
Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives
2024, Journal of Pharmaceutical Sciences
Polyethylene glycol (PEG) is a versatile polymer that is used in numerous pharmaceutical applications like the food industry, a wide range of disinfectants, cosmetics, and many commonly used household products. PEGylation is the term used to describe the covalent attachment of PEG molecules to nanocarriers, proteins and peptides, and it is used to prolong the circulation half-life of the PEGylated products. Consequently, PEGylation improves the efficacy of PEGylated therapeutics. However, after four decades of research and more than two decades of clinical applications, an unappealing side of PEGylation has emerged. PEG immunogenicity and antigenicity are remarkable challenges that confound the widespread clinical application of PEGylated therapeutics — even those under clinical trials — as anti-PEG antibodies (Abs) are commonly reported following the systemic administration of PEGylated therapeutics. Furthermore, pre-existing anti-PEG Abs have also been reported in healthy individuals who have never been treated with PEGylated therapeutics. The circulating anti-PEG Abs, both treatment-induced and pre-existing, selectively bind to PEG molecules of the administered PEGylated therapeutics inducing activation of the complement system, which results in remarkable clinical implications with varying severity. These include increased blood clearance of the administered PEGylated therapeutics through what is known as the accelerated blood clearance (ABC) phenomenon and initiation of serious adverse effects through complement activation-related pseudoallergic reactions (CARPA). Therefore, the US FDA industry guidelines have recommended the screening of anti-PEG Abs, in addition to Abs against PEGylated proteins, in the clinical trials of PEGylated protein therapeutics. In addition, strategies revoking the immunogenic response against PEGylated therapeutics without compromising their therapeutic efficacy are important for the further development of advanced PEGylated therapeutics and drug-delivery systems.
Versatile Biodegradable Poly(acrylic acid)-Based Hydrogels Infiltrated in Porous Titanium Implants to Improve the Biofunctional Performance
2023, Biomacromolecules
This research work proposes a synergistic approach to improve implants’ performance through the use of porous Ti substrates to reduce the mismatch between Young’s modulus of Ti (around 110 GPa) and the cortical bone (20–25 GPa), and the application of a biodegradable, acrylic acid-based polymeric coating to reduce bacterial adhesion and proliferation, and to enhance osseointegration. First, porous commercially pure Ti substrates with different porosities and pore size distributions were fabricated by using space-holder techniques to obtain substrates with improved tribomechanical behavior. On the other hand, a new diacrylate cross-linker containing a reduction-sensitive disulfide bond was synthesized to prepare biodegradable poly(acrylic acid)-based hydrogels with 1, 2, and 4% cross-linker. Finally, after the required characterization, both strategies were implemented, and the combination of 4% cross-linked poly(acrylic acid)-based hydrogel infiltrated in 30 vol % porosity, 100–200 μm average pore size, was revealed as an outstanding choice for enhancing implant performance.
Liposomes and phytosomes: Nanocarrier systems and their applications for the delivery of phytoconstituents
2023, Coordination Chemistry Reviews
Phytochemicals, such as terpenes, polyphenols, and tannins, have been used in history, for the treatment of illnesses and fever. Phytochemicals are easily available in nature, can be isolated easily, and can be used against microbial infections, cancers, and for wound healing. However, due to poor pharmacokinetics, therapeutic applications of phytochemicals are heavily affected. Novel methods have been developed, for carrying and delivering phytochemicals to the target sites in a sustained manner. Liposomes and phytosomes are useful for encapsulating and delivering both lipophilic and hydrophilic therapeutic agents in higher quantity, without being identified by the reticuloendothelial system (RES). Surface modification of these nanocarriers, with polyethylene glycol (PEG), polyacrylic acid (PAA), or poly-L-lactic acid (PLA), has improved the bioavailability and stability. Development of immunoliposomes and immunophytosomes, by conjugating monoclonal antibodies, fragments, or targeting moieties, has improved the active targeting of cancer cells. If conjugated with the cancer specific antibodies, such as anti-HER2, transferrin, and folate, liposomes and phytosomes are capable for identifying and attaching cancer cells more efficiently. Targeted nanocarriers can carry phytochemicals and internalize them into the target cells. Liposomes and phytosomes have improved the wound healing actions of phytochemicals. Codelivery of phytochemicals and therapeutic agents can further eliminate the odds of drug resistance or failure. Such drug delivery systems are able to minimize the enzymatic degradation in gastrointestinal tract, avoid first pass metabolism, and diminish off-target toxicity. Continuous development in this area can further identify the untapped potentials of liposome and phytosome based delivery of natural products and phytochemicals, for therapeutic purpose.
Engineered intravenous therapies for trauma
2023, Current Opinion in Biomedical Engineering
Trauma leading to severe hemorrhage and shock on average kills patients within 3–6 h after injury. With average prehospital transport times reaching 1–6 h in low- to middle-income countries, stopping the bleeding and reversing hemorrhagic shock is vital. First-generation intravenous hemostats rely on traditional drug delivery platforms, such as self-assembling systems, fabricated nanoparticles, and soluble polymers due to their active targeting, biodistribution, and safety. We discuss some challenges in translating these therapies to patients, as very few have successfully made it through preclinical evaluation in large animals, and none have translated to the clinic. Finally, we discuss the physiology of hemorrhagic shock, highlight a new low-volume resuscitant (LVR) PEG-20k, and end with considerations for the rational design of LVRs.
Synthetic pressure sensitive adhesives for biomedical applications
2023, Progress in Polymer Science
Pressure sensitive adhesives are components of everyday products found in homes, offices, and hospitals. Serving the general purpose of fissure repair and object fixation, pressure sensitive adhesives indiscriminately bind surfaces, as long as contact pressure is administered at application. With that being said, the chemical and material properties of the adhesive formulation define the strength of a pressure sensitive adhesive to a particular surface. Given our increased understanding of the viscoelastic material requirements as well as the intermolecular interactions at the binding interface required for functional adhesives, pressure sensitive adhesives are now being explored for greater use. New polymer formulations impart functionality and degradability for both internal and external applications. This review highlights the structure-property relationships between polymer architecture and pressure sensitive adhesion, specifically for medicine. We discuss the rational, molecular-level design of synthetic polymers for durable, removable, and biocompatible adhesion to wet surfaces like tissue. Finally, we examine prevalent challenges in biomedical wound closure and the new, innovative strategies being employed to address them. We conclude by summarizing the progress of current research, identifying additional clinical opportunities, and discussing future prospects.

View all citing articles on Scopus

View full text

Research ArticlesDistribution and Tissue Uptake of Poly(ethylene glycol) with Different Molecular Weights after Intravenous Administration to Mice

Abstract

Biochem. Biophys. Res. Commun.

Biochem. Biophys. Acta.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

J Controlled Release

J Biol. Chem.

Biochem. Biophys. Acta

Computers Biomed. Res.

Biomaterials

Anal. Biochem.

Exp. Cell Res.

J. Hepatol.

Jpn. J. Cancer Res. (Gann).

Clin. Exp. Immunol.

Engl. J. Med.

Proc. Natl. Acad. Sci. U.S.A.

Res. Commun. Chem. Pathol. Pharmacol.

Anal. Biochem.

J. Pharm. Pharmacol.

Research Articles
Distribution and Tissue Uptake of Poly(ethylene glycol) with Different Molecular Weights after Intravenous Administration to Mice